Abstract

The invention relates to a device (2) for additive synthesis via multiphoton polymerisation in a printing volume referred to hereinafter as a voxel (30), the device comprising a print head (21) comprising a body (211) in which a plurality of channels (2111, 2112, 2113, 2114) is formed, each of the channels being configured to allow a polymerisable liquid (40) to flow from an inlet to an outlet, characterised in that each of the channels of the plurality of channels comprises an inlet (2111a, 2112a, 2113a, 2114a) and an outlet (2111b, 2112b, 2113b, 2114b) that are distinct from those of the other channels, and in that the device comprises an alignment module (22) configured to move the print head so as to position the outlet of one of the channels of the plurality of channels opposite the voxel.

IPC Classes  ?

• B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
• B29C 64/209 - HeadsNozzles
• B29C 64/236 - Driving means for motion in a direction within the plane of a layer
• B29C 64/336 - Feeding of two or more materials
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B33Y 40/00 - Auxiliary operations or equipment, e.g. for material handling
• B29C 64/273 - Arrangements for irradiation using laser beamsArrangements for irradiation using electron beams [EB] pulsedArrangements for irradiation using laser beamsArrangements for irradiation using electron beams [EB] frequency modulated

Abstract

The invention relates to the field of identifying a risk of developing type 2 diabetes in a patient. More particularly, it relates to the calculation of a clinical risk score, and optionally to the calculation of an additional genetic risk score, making it possible to estimate a score for the risk of developing type 2 diabetes. The invention also relates to the calculation of an age for developing type 2 diabetes. The clinical risk score is in particular calculated from current clinical data, but also from past clinical data.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

The inventors have now succeeded in developing alkyloxyindole and arylalkyloxyindole compounds, in particular 5-alkyloxyindole, 4-arylalkyloxyindole, 5- arylalkyloxyindole and 6-arylalkyloxyindole compounds, and derivatives. These compounds have the advantage of modulating, in particular inhibiting, the YAP(TAZ)- TEAD interaction, in particular targeting the palmitate pocket. The present invention relates to alkyloxyindole and arylalkyloxyindole compounds and derivatives, including their pharmaceutically acceptable salts and solvates, which are useful as modulators, in particular as inhibitors, of the YAP(TAZ)-TEAD interaction targeting the palmitate pocket, and are useful as therapeutic compounds, particularly in the treatment of cancer.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07D 209/32 - Oxygen atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/04 - Ortho-condensed systems
• C07D 487/14 - Ortho-condensed systems
• A61K 31/404 - Indoles, e.g. pindolol

Abstract

The invention relates to a method for predicting the condition of a person's spine, the method comprising: - making a first estimate (E1) of personalised information about the spine on the basis of first input data (d1); - making a second estimate (E2) of mechanical loads that may be applied to the spine on the basis of second input data (d2); - performing a calculation (E3) to predict the condition of the spine on the basis of the first estimate (E1) and the second estimate (E2).

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

In the present invention, inventors used highly sensitive, classical and/or digital, OMICS technologies, to analyze combined markers profiles in serum of subjects with NAFLD and NASH, at the time of hospital admission or control subjects. Briefly, inventors through the PRECINASH study have access to an unprecedented number of liver and serum samples, from a cohort of > 1000 patients covering the full spectrum of disease progression, from normal liver to NASH. Thereafter, inventors used a supervised statistical approach to identify the biomarkers combinations that represent a reliable biomarker of NAFLD-related severity and elaborate a global Nash score in order to obtain an end value (global NASH Score or PreciNASH score), in order to predict liver-related morbi-mortality in NASH that will help to better define the population of risk, estimate the potential impact of therapeutic intervention on outcomes. This PreciNASH score set may be used as diagnostic or prognosis tool and thus set-up the basis for the development of a rapid functional specific test for NASH disease and also improved personalized patient management and monitoring.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention concerns new tricyclic spirolactams (TriSLas) compounds and their use as a drug, in particular for the prevention and/or treatment of a mycobacterial infection or for the treatment of a disease caused by infection with a mycobacterium. The tuberculosis drug development pipeline requires further supplementation with additional candidates, ideally acting on novel targets (to minimize cross-resistance) and impacting on drug-tolerant bacilli to shorten treatment. The inventors of the present invention have identified new tricyclic spirolactams (TriSLas) compounds with particular activity against M. tuberculosis.

IPC Classes  ?

• C07D 498/10 - Spiro-condensed systems
• A61P 31/10 - Antimycotics
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

Abstract

The present invention relates to a method for producing biomethane from a gas mixture comprising carbon dioxide and methane, which method comprises bringing said mixture into contact with a ruthenium-based catalyst in a hydrogen atmosphere.

IPC Classes  ?

• C10L 3/08 - Production of synthetic natural gas
• B01J 23/46 - Ruthenium, rhodium, osmium or iridium
• C07C 1/12 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon dioxide with hydrogen

Abstract

The invention relates to a stable hydrocarbon composition comprising: (a) 10% to 30% by weight of a renewable base comprising at least one component selected from a biomass pyrolysis oil and a residue of the vacuum distillation of a biomass pyrolysis oil, (b) 70% to 90% by weight of a fossil base containing at least 1% by weight of asphaltenes and having an aromatics content of at most 54% by weight.

IPC Classes  ?

• C10G 3/00 - Production of liquid hydrocarbon mixtures from oxygen-containing organic materials, e.g. fatty oils, fatty acids
• C10L 1/04 - Liquid carbonaceous fuels essentially based on blends of hydrocarbons

Abstract

The present invention belongs to the field of compounds for use in therapeutic treatment, and more particularly hop derived compounds for use in the treatment of diseases caused by coronaviruses. The main field of application is human health, through the development of new active beta-acid-type antivirals against SARS-CoV-2. The present invention relates to hop derived compounds according to the invention for use in the treatment of diseases caused by a virus chosen from coronaviruses belonging to the Coronaviridae family.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/12 - Antivirals

Abstract

OF THE INVENTION LOCAL ADMINISTRATION OF RIPK2 INHIBITORS FOR THE CURATIVE TREATMENT OF ALLERGIC ASTHMA The present invention relates to a method for use in the treatment of Asthma. Here, the inventors identified the receptor-interacting serine/threonione protein kinas 2 (RIPK2) as a novel therapeutic target to improve Asthma-related diseases. They demonstrated that a local preventive administration of the RIPK2 inhibitor reduced AHR, airway eosinophilia, mucus production, Th2 cytokines and the alarmin IL-33. Moreover, they demonstrated the early role of IL-33 in the NOD1-dependent response of the epithelium to HDM. Therefore, the inventors demonstrated that the local interference of the NOD1 signaling pathway through RIPK2 inhibition may represent a new therapeutic approach in asthma. Other pulmonary diseases could also benefit of this treatment. Thus, the present invention relates to a method for use in the curative treatment of HDM-induced asthma comprising administrating to a subject in need thereof a therapeutically effective amount of an inhibitor of RIPK2.

IPC Classes  ?

• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/06 - Antiasthmatics
• A61P 37/08 - Antiallergic agents

Abstract

The invention relates to a method for manufacturing a microelectronic device (100) having a cavity (20) comprising at least one transistor (11a), the method comprising at least the following step:  Removing the materials from a stack of dielectric layers (1) of the microelectronic device (100), selectively with respect to the materials of a set of interconnection lines (2) and a cover (3) of an active area by vapor-phase HF etching, thus forming the cavity (20) extending laterally in a direction x at least until exposing the walls of the set of interconnection lines (2) opposite the first transistor (11a), and in a direction z perpendicular to the direction x until exposing an upper face of the cover (3) of the active area.

IPC Classes  ?

• H01L 21/768 - Applying interconnections to be used for carrying current between separate components within a device
• H01L 23/532 - Arrangements for conducting electric current within the device in operation from one component to another including external interconnections consisting of a multilayer structure of conductive and insulating layers inseparably formed on the semiconductor body characterised by the materials
• H01L 29/78 - Field-effect transistors with field effect produced by an insulated gate
• H01L 23/367 - Cooling facilitated by shape of device

Abstract

jijij2n-11n1nn).

IPC Classes  ?

• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to the treatment of Tauopathies. In this study, the inventors worked on an optimized treatment of Tauopathies, including AD and primary Tauopathies. Previously, the inventors evidenced that Tau pathology is associated with deleterious T-cell-mediated processes that contribute to promote Tau-related detrimental neuroinflammation and cognitive deficits. Considering the unique capacity of immunosuppressive Tregs to inhibit both CD4+ and CD8+ T cell responses, the inventors raise the hypothesis that amplifying Tregs may allow controlling Tau-driven T-cell-mediated detrimental processes in the course of AD and other Tauopathies. They thus evaluated preclinically the impact on disease progression of an optimized IL-2-based Treg-targeting immunomodulatory treatment in the THY-Tau22 mouse model of Tauopathy. They chronically treated THY-Tau22 mice with an optimized IL-2-based treatment, i.e. complexes of IL-2 and anti-IL-2 antibodies (termed herein IL-2C) in order to modulate Tau-associated detrimental T cell responses. Their data supports that this treatment amplifies Tregs more efficiently and selectively than "regular" low dose IL-2 treatment. Furthermore, they hereby showed that IL-2C has a beneficial effect on cognitive deficits since treated THY-Tau22 mice tend to acquire and retain spatial information more potently than untreated littermates. Thus, the invention relates to an IL-2/anti-IL-2 complex (IL-2C) for use in the treatment of Tauopathies.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 38/20 - Interleukins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to a flame-retardant material composition for use in 3D printing, comprising or consisting of: - 30% to 60% by weight, relative to the total weight of the composition, of at least one polyolefin from renewable or petroleum-based resources; - 5% to 20% by weight, relative to the total weight of the composition, of at least one fibrous material; - 20% to 50% by weight, relative to the total weight of the composition, of at least one intumescent agent acting in the condensed phase; - 2.5% to 20% by weight, relative to the total weight of the composition, of at least one flame retardant acting in the gas phase; - 0.5% to 5% by weight, relative to the total weight of the composition, of at least one inorganic compound selected from zeolites or zeolitic materials, montmorillonites, vermiculites, silicates, aluminas, magnesium oxides, zinc oxides and a mixture of two or more thereof.

IPC Classes  ?

• C08K 3/22 - OxidesHydroxides of metals
• C08K 3/34 - Silicon-containing compounds
• C08K 5/52 - Phosphorus bound to oxygen bound to oxygen only
• C08K 5/5313 - Phosphinic compounds, e.g. R2=P(:O)OR'
• C08K 7/06 - Elements
• C08K 7/14 - Glass
• C08L 23/06 - Polyethene
• C08L 23/12 - Polypropene

Abstract

The present application relates to pyrazole derivatives as PD-1/PD-L1 interaction inhibitors. The applicants designed compounds of general formula (I), wherein R', R2, y3, R3, R4, R5, R6and R7in vitroin vitro biological tests (FRET assay, Promega Blockade assay, T cell assay). These compounds had an affinity (Kd) of the order of pM that was higher than that of the antibody atezolizumab used in clinical use, and had a comparable or better IC50 than that observed with atezolizumab. Thus, the present invention also relates to a pharmaceutical composition comprising said compound(s) and their uses in the treatment of PD-1-PD-L1 interactions-related diseases (cancer, chronic inflammatory diseases, neurological diseases and chronic infections).

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• C07D 231/40 - Acylated on said nitrogen atom
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings

Abstract

METHODS OF TREATMENT OF METABOLIC DISORDERS In the present invention SLC5A9 gene (encoding SGLT4 protein) regulation was analyzed in the intestine of patients before and after weight-loss surgery. RNA scope analysis was used to determine the precise location of SLC5A9 in the human intestine and pancreas. Sglt4 knock- out (KO) mice were created using CRISPR/Cas techniques, allowing to study changes in their metabolic phenotype for months while they were fed the WD (Western Diet). So, these data demonstrate that SLC5A9 mRNA levels are induced in the apical membrane of the intestine and exocrine pancreas in persons with obesity and Type 2 Diabetes. Furthermore, Sglt4 deficiency slows the onset of obesity and hyperglycemia in mice fed the WD, improving insulin sensitivity by improving beta cell function. Accordingly the present invention relates to a method for preventing or treating metabolic disorders by targeting the Sodium-Glucose-Co- Transporter-4 (SGTL4).

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C40B 30/06 - Methods of screening libraries by measuring effects on living organisms, tissues or cells
• G01N 33/15 - Medicinal preparations
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
• A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

LDLrLDLr -/-PPARαLDLrLDLr -/- PPARαPPARα +/+LDLrLDLr -/- PPARαPPARα -/-LDLrLDLr -/- PPARαPPARα +/+LDLrLDLr -/- PPARαPPARα +/+LDLrLDLr -/- PPARαPPARα +/+ mice. The present invenion defines a new relevant mouse model of progressive MASLD, developing all the characteristics of human MASLD (steatosis, inflammation, ballooning, fibrosis), in a relatively short time period (12-18 weeks), along with simultaneous atherosclerosis development.

IPC Classes  ?

• A01K 67/0276 - Knock-out vertebrates

Abstract

The invention relates to a material comprising porous microspheres on an actinide oxide basis, which is obtained by an internal gelation method. It also relates to the uses of this material in the manufacture of nuclear fuels, in particular as a sintering additive in the manufacture of pellets of an MOX (mixed oxide) type nuclear fuel and, more specifically, as a pore-forming agent replacing the pore-forming agent conventionally used in said manufacture, namely azodicarbonamide.

IPC Classes  ?

• G21C 3/62 - Ceramic fuel

Abstract

Provided are closed systems methods of use for isolation of mammalian tissues.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The invention concerns a new galenic formulation of CFT (clofoctol) allowing the administration of this antibiotic in aerosol form with the objective of treating pulmonary infections (COVID-19, influenza), cancer and inflammation thus targeting the diseased tissue while avoiding the problems of solubility of CFT and toxicity associated with this drug. This new formulation allows to answer these problems and concerns the development of polymeric nanoparticles (Nanoparticles) in suspension in an aqueous phase intended to be administrated in a form of aerosol or spray, said Nanoparticles comprising PLGA and PLGA-PEG polymers, allowing to obtain an effective encapsulation of CFT and a controlled release of CFT at the pulmonary level.

IPC Classes  ?

• A61K 9/51 - Nanocapsules

Abstract

The present description relates to a haptic feedback device comprising a panel defining a contact surface intended to be touched by an external body, and piezoelectric actuators (14) configured to make the panel vibrate, the piezoelectric actuators being connected in parallel to a first inductive element (Lp) and, via a second series inductive element (Ls), to a circuit (2) for applying an AC voltage.

IPC Classes  ?

• B06B 1/02 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy
• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

Disclosed are modified cytokines which, relative to wild-type forms, comprise one or more amino acid modifications. Relative to the activity of wild type cytokines, these modified cytokines exhibit enhanced activity at an acidic pH and often reduced activity at neutral pH. The disclosed modified cytokines are for use in medicine and/or for the treatment and/or prevention of an immunological condition or cancer.

IPC Classes  ?

• C07K 14/55 - IL-2
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a coating composition that cannot be wetted by liquid zinc, characterised in that the composition comprises the metallic elements of nickel (Ni), chromium (Cr), silicon (Si), phosphorus (P) and optionally boron (B) in the following proportions: Ni 50%-60%, Cr 20%-30%, Si 5%-12%, P 4%-8%, and B 0%-1.5% by weight relative to the total weight of the metallic elements present in the coating composition; and to the uses thereof. The invention further relates to a method for coating at least one surface of a metal part and to a metallic coating that cannot be wetted by liquid zinc. The invention also relates to a metal part coated with a metallic coating that, according to the invention, cannot be wetted by liquid zinc.

IPC Classes  ?

• C23C 2/00 - Hot-dipping or immersion processes for applying the coating material in the molten state without affecting the shapeApparatus therefor
• C22C 19/05 - Alloys based on nickel or cobalt based on nickel with chromium
• C23C 24/08 - Coating starting from inorganic powder by application of heat or pressure and heat
• C23C 30/00 - Coating with metallic material characterised only by the composition of the metallic material, i.e. not characterised by the coating process

Abstract

The present invention proposes a method for manufacture of an endoprosthesis, in particular a vascular endoprosthesis, comprising the 3D printing (100) of a hollow membrane made of thermoplastic elastomer, and the fastening (200) of a collapsible metal framework to the hollow membrane in order to form a membrane-framework assembly. The fastening comprises (i) the 3D printing (201) of an additional membrane made of thermoplastic elastomer, the arranging (202) of the collapsible metal framework between the hollow membrane and the additional membrane in order to obtain an assembly, the immersion soaking (204) of the assembly in an organic solvent in order to obtain the membrane-framework assembly, and the drying (205) of the membrane-framework assembly; or (ii) the arranging (212) of the collapsible metal framework on the hollow membrane in order to obtain an assembly, and the dip coating (214) in a solution in an organic solvent, and then the drying (215) of the assembly.

IPC Classes  ?

• A61F 2/07 - Stent-grafts

Abstract

The present disclosure relates to conjugates of catechol-based siderophores with cargo molecules, such as antibiotics or fluorophores, and to the preparation and uses thereof.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 49/00 - Preparations for testing in vivo
• A61P 31/04 - Antibacterial agents
• C07D 211/94 - Oxygen atom, e.g. piperidine N-oxide
• C07D 223/12 - Nitrogen atoms not forming part of a nitro radical
• C07D 277/10 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 323/00 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
• C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
• C07D 491/16 - Peri-condensed systems
• C07D 493/10 - Spiro-condensed systems
• C07D 498/08 - Bridged systems
• C07D 499/64 - Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms

Abstract

Glutamatergic neurons produce, accumulate and release in synapses the neurotransmitter glutamate, which is the main excitatory neurotransmitter in the mammalian central nervous system. Said neurons are involved in most of the brain's fundamental processes such as cognition, learning, memory, and sensory perception. There is an interest to identify transcription factor that would allow the differentiation towards glutamatergic neurons. The inventors surprisingly show that overexpression of ASCL1 induces the generation of a highly pure population of glutamatergic neurons. Said observation goes totally in the opposite direction of what has been previously taught, since ASLC1 was mainly described as inducing GABAergic neurons in the forebrain. Therefore, the present invention relates to methods for generating highly pure glutamatergic neuronal populations using the pro-neural factor ASCL1.

IPC Classes  ?

• C12N 5/0793 - Neurons

Abstract

The present invention pertains to an inner ear implant for controlled release of an active ingredient comprising the active ingredient and polyethylene vinyl acetate (EVA).

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Abstract

The present disclosure relates to a controlled release delivery dosage form for controlled release of an active ingredient, comprising a core comprising said active ingredient, coated by a polymeric mixture of at least a water insoluble polymer, and at least a polysaccharide extract selected from the group consisting of aqueous aloe vera extract and aqueous reishi extract, their methods of producing and uses thereof.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 31/606 - Salicylic acidDerivatives thereof having amino groups

Abstract

Polyphase electric machine including a first motion actuation assembly and a rotatable second motion actuation assembly, the first and second motion actuation assemblies together defining first and second opposing lateral faces, of the polyphase electric machine; the polyphase electric machine further having at least one phase generator including a plurality of control assemblies, each control assembly containing an input module and an output module, the input and output modules being arranged on the first lateral face and on the second lateral face of the polyphase electric machine.

IPC Classes  ?

• H02K 9/22 - Arrangements for cooling or ventilating by solid heat conducting material embedded in, or arranged in contact with, the stator or rotor, e.g. heat bridges
• H02K 1/02 - Details of the magnetic circuit characterised by the magnetic material
• H02K 1/276 - Magnets embedded in the magnetic core, e.g. interior permanent magnets [IPM]
• H02K 9/20 - Arrangements for cooling or ventilating for machines with closed casing and closed-circuit cooling using a liquid cooling medium, e.g. oil wherein the cooling medium vaporises within the machine casing
• H02K 11/33 - Drive circuits, e.g. power electronics

Abstract

The gut-to-lung axis is critical during respiratory infections, including influenza A virus (IAV) infection. In the present study, the inventors used high-resolution shotgun metagenomics and targeted metabolomics analyses to characterize influenza-associated changes in the mouse gut microbiota's composition and metabolism. Quantitative targeted metabolomics analysis of serum revealed changes in specific classes of gut microbiota metabolites, including SCFAs, indole-containing tryptophan metabolites, trimethylamine, and polyamines. The changes in microbiota-associated metabolites were correlated with changes in taxon abundances and levels of disease markers. For instance, the tryptophan metabolite indole-3-propionic acid (IPA) was correlated positively with some Bacillota species but negatively with Bacteroidales bacteria M7, the viral load, and inflammation markers. Given its marked fall during infection, the inventors tested the effects of IPA supplementation in diseased animals. This supplementation was associated with a lower viral load and lower levels of local (lung) and systemic inflammation during influenza. Taken as a whole, the results highlighted IPA as both an important metabolic modulator to disease severity and a potential biomarker of influenza outcomes.

IPC Classes  ?

• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention relates to an interface for preparing biological material for transfer into a mass spectrometer. The interface comprises a tube delivering the biological material in the form of an aerosol, a venturi system with two inlets and one outlet, a heating cartridge, a corona discharge needle for ionizing the biological material in aerosol form, a nebulizer for generating a mist, and a transfer tube connected to the outlet of the venturi system. The interface is arranged such that the heating cartridge is placed around the transfer tube, the corona discharge needle is located at the outlet of the transfer tube, and the venturi system is connected to the tube delivering the biological material and to the nebulizer by means of the two inlets, leading to the solvation of the biological material in aerosol form by the mist in the venturi system.

IPC Classes  ?

• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
• H01J 49/16 - Ion sourcesIon guns using surface ionisation, e.g. field-, thermionic- or photo-emission

Abstract

The present invention relates to an interface (1) for preparing material, in particular biological material, for transfer into a mass spectrometer, the material being in the form of an aerosol, the interface comprising an ionization device (2) for generating an ionized mist, and an ionization chamber (3) having a material inlet, a mist inlet for bringing the material in contact with the ionized mist in a mixing zone, the ionization device being configured to generate the ionized mist upstream of the mixing zone. The invention also relates to a method for preparing material using an interface of said kind.

IPC Classes  ?

• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
• H01J 49/14 - Ion sourcesIon guns using particle bombardment, e.g. ionisation chambers
• H01J 49/16 - Ion sourcesIon guns using surface ionisation, e.g. field-, thermionic- or photo-emission

Abstract

The invention relates to a microfluidic device (1) for forming a cell assembly comprising at least one first cell (C1) and one second cell (C2) and for individually treating a selected cell of said cell assembly, comprising: - a microfluidic channel (10); - at least one main inlet (11) for a fluid containing first cells, respectively second cells, arranged in a first portion (101) of the microfluidic channel; - an outlet (12) arranged in a second portion (102) of the microfluidic channel for controlling a fluid flow rate in the microfluidic channel; - at least one first auxiliary inlet (131) for a first auxiliary fluid arranged in the first portion (101) of the microfluidic channel upstream or downstream of the main inlet (11); - at least one cell trap (14) arranged in the microfluidic channel between the first portion and the second portion, wherein each cell trap (14) comprises at least one first trapping portion (141) and one second trapping portion (142), each first and second trapping portion being sized to receive a respective first or second cell, said first and second trapping portions being adjacent to each other in a direction perpendicular to a bottom (100) of the microfluidic channel to form the cell assembly with the trapped first and second cells, each cell being at a different height relative to the bottom of the microfluidic channel, - at least one first valve for controlling a flow rate of the first auxiliary fluid so as to cause the fluid containing the first cells, respectively the second cells, to flow at a determined height in the microfluidic channel in order to bring the first cell, respectively the second cell, to the first trapping portion, respectively to the second trapping portion.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The invention relates to a photovoltaic panel (1) comprising a protective plate (5) having an outer face (9) and a cleaning device arranged to clean a surface of the outer face, the cleaning device comprising at least one transducer (11) acoustically coupled to the protective plate (5) and an electrical control system arranged to generate an electrical signal and to apply it across the terminals of the transducer to produce an acoustic wave that propagates through the protective plate, the acoustic wave being a surface wave or a Lamb wave and being such that, under the effect of the acoustic wave, solid-state elements (8), such as grains of sand or dust particles, which may be found on the surface of the outer face, are moved and cleared from the surface.

IPC Classes  ?

• H02S 40/10 - Cleaning arrangements
• H02S 40/30 - Electrical components
• B08B 7/02 - Cleaning by methods not provided for in a single other subclass or a single group in this subclass by distortion, beating, or vibration of the surface to be cleaned

Abstract

The invention relates to a method for cleaning solid-state elements (8), such as grains of sand or dust particles, that may be found on a surface of a body (5), the cleaning method using at least one transducer (11) acoustically coupled to the body and comprising the steps of: - generating an electrical signal; - applying the electrical signal across the terminals of the transducer; - thereby producing an acoustic wave that propagates through the body, the acoustic wave being a surface wave or a Lamb wave and being such that, under the effect of the acoustic wave, the solid-state elements are moved over the surface of the body in order to be cleared from this surface.

IPC Classes  ?

• H02S 40/10 - Cleaning arrangements
• H02S 40/30 - Electrical components
• B08B 7/02 - Cleaning by methods not provided for in a single other subclass or a single group in this subclass by distortion, beating, or vibration of the surface to be cleaned

Abstract

The present invention relates to a method for characterizing a lubricant for an electric machine, the method involving: - a step of acquiring a lubricant spectrum by implementing an electronic paramagnetic resonance technique, and - analyzing the acquired spectrum to determine the quantity of superparamagnetic iron oxide nanoparticles contained in the lubricant.

IPC Classes  ?

• G01N 24/10 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using electron paramagnetic resonance
• G01R 33/60 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using electron paramagnetic resonance

Abstract

CMCMC CPCPC , , the bolus being equal to a predetermined first quantity of the compound when the sum of the first and second fuzzy logic variables is strictly greater than 1, the bolus otherwise being equal to zero.

IPC Classes  ?

• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to a method for oxydesulfurization (oxidative desulfurization) of at least one heavy fuel oil using a catalyst in the form of platelets having an ordered two-dimensional hexagonal mesoporous structure, as well as to the use of such a catalyst in the form of platelets having an ordered two-dimensional hexagonal mesoporous structure, for oxydesulfurization of at least one heavy fuel oil.

IPC Classes  ?

• C10G 27/12 - Refining of hydrocarbon oils, in the absence of hydrogen, by oxidation with oxygen or compounds generating oxygen with oxygen-generating compounds, e.g. per-compounds, chromic acid, chromates
• B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
• C10G 53/14 - Treatment of hydrocarbon oils, in the absence of hydrogen, by two or more refining processes plural serial stages only including at least one oxidation step

Abstract

Therapeutic resistance is one of the major challenges in cancer treatment. These latter may be inherently resistant or this resistance may be acquired during treatment. In this context, the tau protein, encoded by the MAPT gene, could prove to be an important contributor in resistance to cancer therapy. The inventors have been thus abled to confirm in vivo that the tau protein was a factor of resistance to radiotherapy and the chemotherapy inducing DSB (doxorubicin) and that the reduction of its expression by shRNA increased the sensitivity of tumors to these treatments. The present invention relates to a method for decreasing therapeutic acquired resistance to chemotherapy agent and/or radiotherapy agent in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a Tau inhibitor.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 35/00 - Antineoplastic agents
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

According to one aspect, the present description relates to a system (100) for analysing a gaseous biological sample, the system comprising a device (110) for collecting the gaseous biological sample; a time-domain spectroscopy measurement device (120) comprising a gas analysis cell (122) configured to receive the gaseous biological sample and electromagnetic detection means configured to detect at least one first sample time trace (Es(t)), each sample time trace resulting from coherent detection of a sample beam arising from the gas analysis cell traversed by a THz excitation beam; a processing unit (130) comprising a pre-trained machine learning module for detecting at least one state of a subject, wherein the processing unit is configured to calculate a sample estimator on the basis of the at least one sample time trace and to determine, from the at least one estimator and using the machine learning module, the at least one state of the subject.

IPC Classes  ?

• G01N 21/3586 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared lightInvestigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using Terahertz radiation by Terahertz time domain spectroscopy [THz-TDS]
• G01N 21/3504 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing gases, e.g. multi-gas analysis

Abstract

A method for producing a measuring device (10) with a microflow channel (22) is provided. The device (10) includes an electrical sensing module (30) including at least two electrodes (32, 34) for characterizing objects in fluid flow. The method involves preparation of an SOI substrate (100) including top and bottom semiconductor layers (90, 50) and an intermediate oxide layer (70). The top layer is patterned to form a cavity defining the flow channel, the electrodes and a gap (92) adjacent to the respective electrodes along the flow channel. Then an insulating material (80, 82) is applied to each gap to form an insulating filling (81) for electrically insulating the electrical sensing module from the remaining top layer. The corresponding measuring device (10) is also provided.

IPC Classes  ?

• G01N 15/10 - Investigating individual particles
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 15/1031 - Investigating individual particles by measuring electrical or magnetic effects

Abstract

Inventors have isolated a single-domain antibody (designated KB-VWF-D3.1) targeting the A3-domain, the epitope of which overlaps the collagen-binding site. Binding of KB-VWF-D3.1 proved independent of VWF multimer size. However, its interaction with VWF was lost upon proteolysis by ADAMTS13, suggesting that proteolysis in the A2-domain modulates exposure of its epitope in the A3-domain. Inventors therefore used KB-VWF-D3.1 to monitor VWF degradation in plasma samples. Spiking experiments showed that a loss of 10% intact-VWF could be detected using this single-domain antibody. By comparing plasma from volunteers to that of congenital VWD-patients, intact-VWF levels were significantly reduced for all VWD-types, and most severely in VWD-type 2A(IIA) in which mutations promote ADAMTS13-mediated proteolysis. Unexpectedly, low-grade proteolysis in VWD-type 1 and -type 2M was also observed. Thus, this single-domain antibody proved sensitive to detect low-grade degradation in plasma from patients with AVWS and congenital VWD, including types 1 and 2M. The present invention relates to an isolated single domain antibody targeting at least one region of A3-domain of VWF, wherein the region comprising the following sequences: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and/or SEQ ID NO: 4.

IPC Classes  ?

• C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors

Abstract

ApicomplexaToxoplasmaT. gondii T. gondii T. gondii morphology and inhibiting intracellular replication. The findings highlight the advantage of comparative and targeted phenotypic analysis involving two related parasite species as a means of identifying molecules with a conserved mode of action.

IPC Classes  ?

• C12Q 1/18 - Testing for antimicrobial activity of a material
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• C07K 14/45 - Toxoplasma
• C12N 1/10 - ProtozoaCulture media therefor
• C12N 15/09 - Recombinant DNA-technology
• G01N 21/00 - Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

mmmm), at least one photodiode (21; 22) operating in photovoltaic mode, connected to the gate of this transistor, such that the drain-source current of the MOS transistor increases when the current generated by the photodiode decreases and vice versa.

IPC Classes  ?

• H04N 25/772 - Pixel circuitry, e.g. memories, A/D converters, pixel amplifiers, shared circuits or shared components comprising A/D, V/T, V/F, I/T or I/F converters

Abstract

BlastocystisBlastocystisBlastocystisBlastocystis sp. in fecal samples obtained from heifers, for predicting productive longevity in heifers, and for improving dairy herd management.

IPC Classes  ?

• C12Q 1/6893 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa

Abstract

12mxww — 1) bits, each element of the matrix product being the sum of dot products (II), the operations leading to the dot product by applying, to logic gates, the values of these vectors and those of associated temporal masks PX and PW so as to generate at least one control signal SC for at least one current source, the control signal SC activating the at least one current source so as to accumulate capacitive charge in an accumulation line.

IPC Classes  ?

• G06N 3/063 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using electronic means
• G06F 17/16 - Matrix or vector computation

Abstract

Bacillus SubtilisBacillus Subtilis strains producing new isoforms of mycosubtilins, a preparation method therefor, and compositions containing same. These novel mycosubtilin isoforms have improved antifungal activities and decreased cytotoxic properties compared with the mycosubtilins of the prior art.

IPC Classes  ?

• C07K 7/64 - Cyclic peptides containing only normal peptide links
• C07K 14/32 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bacillus (G)
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• A61P 31/10 - Antimycotics

Abstract

According to one aspect, the present invention relates to a coupler (400) comprising: a first double-clad hollow-core optical fibre (430) comprising a hollow core (431) configured for guiding light in a first wavelength range and comprising a given damage temperature, and a highly multimodal inner cladding (435) configured for guiding light in a second wavelength range; a second optical fibre (460) comprising a highly multimodal guiding glass portion (461) configured for guiding light in a third wavelength range, the glass having a glass transition temperature which is lower than the damage temperature; a zone (401) for optical coupling between the first fibre and the second fibre, generated by fusion between a region of the inner cladding of the first fibre and a region of the guiding glass portion of the second fibre.

IPC Classes  ?

• G02B 6/28 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals
• G02B 23/26 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes using light guides
• G02B 6/02 - Optical fibres with cladding
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• G02B 23/24 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

A microstructured substrate comprising a main body and a plurality of elongated elementary microstructures extending from the main body, wherein the microstructured substrate comprises a plurality of nanowires positioned on at least one area of the surface of the main body and on the surface of the elementary microstructures that extend from the main body over said area.

IPC Classes  ?

• H01G 11/26 - Electrodes characterised by their structure, e.g. multi-layered, porosity or surface features
• H01G 11/28 - Electrodes characterised by their structure, e.g. multi-layered, porosity or surface features arranged or disposed on a current collectorLayers or phases between electrodes and current collectors, e.g. adhesives
• H01G 11/46 - Metal oxides
• H01G 11/70 - Current collectors characterised by their structure
• H01M 4/04 - Processes of manufacture in general
• H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 10/04 - Construction or manufacture in general
• H01M 4/134 - Electrodes based on metals, Si or alloys
• C23C 16/06 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the deposition of metallic material
• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
• C23C 16/56 - After-treatment
• C23C 16/04 - Coating on selected surface areas, e.g. using masks
• C23C 16/02 - Pretreatment of the material to be coated

Abstract

The inventors have now succeeded in developing novel compounds comprising a diphenylpyrazole scaffold bearing amino side chains. These compounds have the advantage of repressing the production of Aβ1-x and modulating the ratio of autophagy markers with higher efficacy than chloroquine and compounds of the prior art, in particular compounds of the prior art, The present invention is thus directed to compounds of Formula (I) including their pharmaceutically acceptable salts and solvates which have the ability to repress the production of Aβ1-x peptides and to modulate the ratio of autophagy markers, and which are useful as therapeutic compounds, particularly in the treatment and/or prevention of diseases involving the formation of amyloid plaques and/or in which dysfunction of the APP metabolism occurs.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 231/22 - One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms

Abstract

The subject matter of the present invention is a method for producing such components, the components that can be obtained by this method and the use of these components in the production of a liquid organic electrolyte electrochemical cell.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 50/414 - Synthetic resins, e.g. .thermoplastics or thermosetting resins
• H01M 50/446 - Composite material consisting of a mixture of organic and inorganic materials

Abstract

The present disclosure relates to a pharmaceutical injectable solution comprising dopamine or a pharmaceutically acceptable salt thereof, preferably dopamine hydrochloride, dissolved in water for injection, wherein the solution has a pH between 3.0 and 5.5, and has an oxygen content equal to or lower than 0.008% (8 ppm), and uses thereof.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

Abstract

The present invention relates to a surgical insert (1) comprising a first layer (11), and a second layer (12), wherein the first layer and the second layer comprise orifices (111, 121) having an eight shape.

IPC Classes  ?

• A61F 2/30 - Joints
• A61B 17/60 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor for osteosynthesis, e.g. bone plates, screws or setting implements for external osteosynthesis, e.g. distractors or contractors

Abstract

The present invention relates to a surgical insert (1) comprising a first layer (11) and a second layer (12), wherein the first layer and the second layer comprise openings (111, 112) having a figure-of-eight shape. The invention also relates to a bone cement comprising a pulverulent solid phase that comprises natural polysaccharides and a ceramic filler, a liquid acrylate, and a polymerising agent.

IPC Classes  ?

• A61F 2/30 - Joints
• A61L 27/10 - Ceramics or glasses
• B33Y 70/00 - Materials specially adapted for additive manufacturing

Goods & Services

Computer software, recorded; Map software; Apparatus and instruments for geolocation; Databases; Ships logs [electronic]; Computer software for accessing information directories that may be downloaded from the global computer network; downloadable software for the management and transmission of information; Application software; Downloadable software applications; Computer application software; Downloadable mobile applications for the management of data; Downloadable mobile applications for the transmission of data; Downloadable mobile applications for the transmission of information; Computerised applications, For use with the following goods: Vehicle and aircraft navigation apparatus; Data collection apparatus; Computer hardware for the collection of positioning data. Collection of data; Automated processing of medical data. Telecommunication services; Information about telecommunication; Providing access to databases; Electronic bulletin board services [telecommunications services]; Television broadcasting; Geolocation services [telecommunications services]; Transmission of information by data communications for assisting decision making; Transmission of information by electronic means. Traffic information; Information affairs, in relation to the following fields: Medical transport by helicopter. Computer software design; Software development; Updating of computer software; Software as a service [SaaS]; Electronic data storage; Hosting of mobile applications; Development of computer software application solutions; Marine, aerial and land surveying. Medical services; Hospital services; Medical assistance.

Abstract

Here the inventors applied PDAC-derived CAF secretome on pancreatic cancer cells and evaluated Sig-1R implication in stromal cues integration by PCC from signaling transmission to biological outcomes, at the cellular and physiological level. They demonstrated that the loss of Sig-1R in epithelial cells inhibits stromal-induced tumor growth and metastatic process. Thus, the inventors demonstrate that Sig-1R is a key actor of the dialog between stromal and cancer cell compartments The present invention relates to method for the treatment of pancreatic cancer in a patient in need thereof comprising a therapeutically effective amount of a Sig-1R ligand.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents

Abstract

A process to catalyse a chemical reaction to obtain a product, said process comprising the step of reacting a metal or acid catalyst in a solid state, a substrate and a liquid medium, said liquid medium comprising a liquid metal or a liquid metal alloy, wherein the mass ratio of said liquid metal or liquid metal alloy to said catalyst is at least 0.1. The invention further relates to an heterogenous catalyst system comprising a metal or acid catalyst in a solid state and a liquid metal or liquid metal alloy, wherein said catalyst is in contact with a liquid medium, said liquid medium comprising said liquid metal or said liquid metal alloy, and wherein the mass ratio of said liquid metal or said liquid metal alloy to said catalyst is at least 0.1.

IPC Classes  ?

• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 35/12 - Liquids or melts
• B01J 29/70 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of types characterised by their specific structure not provided for in groups
• B01J 23/14 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of germanium, tin or lead
• B01J 23/18 - Arsenic, antimony or bismuth
• B01J 23/34 - Manganese
• B01J 23/42 - Platinum
• B01J 23/44 - Palladium
• B01J 23/62 - Platinum group metals with gallium, indium, thallium, germanium, tin or lead
• B01J 23/644 - Arsenic, antimony or bismuth
• C07C 29/50 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups with molecular oxygen only
• C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
• C07C 67/40 - Preparation of carboxylic acid esters by oxidation of groups which are precursors for the acid moiety of the ester by oxidation of primary alcohols
• C07C 45/29 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation of hydroxy groups
• C07C 45/28 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation of —CHx-moieties
• C07C 45/46 - Friedel-Crafts reactions
• C07C 51/23 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation with molecular oxygen of oxygen-containing groups to carboxyl groups
• C07C 51/235 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation with molecular oxygen of oxygen-containing groups to carboxyl groups of —CHO groups or primary alcohol groups

Abstract

The present disclosure relates to a hydrogel composition based on anionic cyclodextrin polymers and chitosan for use in the treatment of articular disorders. In particular, the hydrogel combines a pharmacological action, in particular an analgesic action, with a visco- supplementation (a lubricating effect).

IPC Classes  ?

• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

The invention relates to a method for protection against oxidation of a composite material part comprising carbon, said method comprising: - impregnating an internal porosity of the part with an impregnation composition comprising, as percentages by weight: (i) between 1% and 60% of colloidal silica; (ii) between 0.5% and 20% of a flux precursor comprising at least one nitrate of an alkali metal M1; (iii) between 0.5% and 20% of a lattice modifying precursor, comprising at least one nitrate or one oxynitrate of an element M2 which is chosen from metals or lanthanides; and (iv) between 20% and 88% of water; and - carrying out a vitrification heat treatment on the part impregnated with the impregnation composition so as to obtain a glass for protection against oxidation comprising at least silica, an oxide of M1 and an oxide of M2.

IPC Classes  ?

• C04B 41/85 - Coating or impregnating with inorganic materials
• F16D 69/02 - Composition of linings
• C03C 3/078 - Glass compositions containing silica with 40% to 90% silica by weight containing an oxide of a divalent metal, e.g. an oxide of zinc

Abstract

Chronic obstructive pulmonary disease is a major clinical challenge mostly due to cigarette smoke exposure and affects more than 200 million people. The inventors tested if exposure to the Bordetella pertussis BPZE1 stain could modulate outcomes of chronic exposure to cigarette smoke in mice. In particular, they showed in mice chronically exposed to cigarette smoke that preventive and/or curative vaccination using BPZE1 could limit the lung inflammation and strongly contribute to the prevention of lung function decline. BPZE1 vaccination modulated pulmonary antigen presenting cells (macrophages and dendritic cells) to switch the immune response, by decreasing the IL-17 inflammatory pathway involved in the pathology of COPD itself, and by favouring a tolerogenic response (IL-10). Together, the data show that vaccination with BPZE1 of mice chronically exposed to cigarette smoke limits the development of chronic obstructive pulmonary disease outcomes and thus represents an interesting therapy.

IPC Classes  ?

• A61K 39/02 - Bacterial antigens
• A61P 11/00 - Drugs for disorders of the respiratory system
• C12N 1/36 - Adaptation or attenuation of cells
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C07K 14/235 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bordetella (G)
• A61K 35/74 - Bacteria
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C12N 9/10 - Transferases (2.)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12R 1/01 - Bacteria or actinomycetales
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The present invention relates to a fibre (1) comprising a core (11) made of a fiberisable material and having an outer surface (111), the fibre being characterised in that it further comprises an outer coating (2) comprising a mixture of hexagonal boron nitride and bentonite, in a proportion of at least 10 wt.% of bentonite relative to the total weight of the outer coating (2). The present invention also relates to an optical component comprising one or more optical fibres (1) according to the invention. Finally, the present invention also relates to a method for producing a pasty composition for fibre coating.

IPC Classes  ?

• C03C 25/106 - Single coatings
• C03C 25/1065 - Multiple coatings
• G02B 6/10 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type

Abstract

The present invention relates to the use of optical fibres comprising a boron nitride (BN)-based coating, in a method for the additive manufacturing of ceramic structures. The present invention also relates to ceramic structures obtained by additive manufacturing comprising an optical component including one or more optical fibres as defined above.

IPC Classes  ?

• C03C 25/106 - Single coatings
• C03C 25/1065 - Multiple coatings
• G02B 6/10 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
• C03C 25/104 - Coating to obtain optical fibres
• C01B 21/064 - Binary compounds of nitrogen with metals, with silicon, or with boron with boron
• C01B 33/20 - Silicates
• C03C 25/12 - General methods of coatingDevices therefor
• C03C 25/42 - Coatings containing inorganic materials
• G02B 6/02 - Optical fibres with cladding

Abstract

The invention provides a method for characterising the state of health of at least one electrochemical element (24) of a battery (20), the battery (20) being a battery having a paramagnetic element with a solid or gel electrolyte, the method comprising a step of: - acquiring data relating to the at least one electrochemical element (24), the data comprising a spectrum obtained via the use of an electron paramagnetic resonance technique or an image obtained via the use of an electron paramagnetic resonance technique; and - analysing the acquired data to detect the presence or absence of an abnormal structure of the paramagnetic element in the at least one electrochemical element (24).

IPC Classes  ?

• H01M 10/48 - Accumulators combined with arrangements for measuring, testing or indicating the condition of cells, e.g. the level or density of the electrolyte
• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
• G01R 31/36 - Arrangements for testing, measuring or monitoring the electrical condition of accumulators or electric batteries, e.g. capacity or state of charge [SoC]
• G01R 31/392 - Determining battery ageing or deterioration, e.g. state of health
• G01R 33/60 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using electron paramagnetic resonance
• G01N 24/10 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using electron paramagnetic resonance
• H01M 10/052 - Li-accumulators

Abstract

The present invention relates to an all-solid-state-battery (ASSB) comprising an anode comprising a first solid electrolyte, a cathode composite comprising a second solid electrolyte, a solid electrolyte chosen from the group consisting in the first and the second solid electrolyte, and at least one buffer layer, in contact with a surface of the solid electrolyte, wherein when the solid electrolyte is the first solid electrolyte, one buffer layer is at the interface of said electrolyte with the cathode, and when the solid electrolyte is the second solid electrolyte, one buffer layer is at the interface of said electrolyte with the anode, wherein the first electrolyte is chosen from a sulphide solid electrolyte and a lithium oxide solid electrolyte, wherein the second electrolyte is a halide solid electrolyte, and wherein the buffer layer has a thickness ranging from 0.5 to less than 10 nm. The invention further pertains to an anode assembly, a cathode assembly and an electrolyte assembly comprising at least one buffer layer. The invention also relates to a process for making an ASSB or an assembly according to the invention wherein the buffer layer is deposited by a vapor deposition based method.

IPC Classes  ?

• H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/134 - Electrodes based on metals, Si or alloys
• H01M 4/40 - Alloys based on alkali metals
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/0562 - Solid materials

Abstract

Exacerbation of heart failure, better known as acute decompensated heart failure (HF), is characterized by dyspnea, edema and fatigue, and is a growing medical problem. The inventors demonstrated that transient O-GlcNAcase inhibition would be suitable for the treatment of acute decompensated heart failure. In particular they used two recently developed models mimicking acute decompensation of heart failure patients, and deciphered mechanisms susceptible to be involved in this cardiovascular protection, with a focus on post-translational cardiac protein modifications and metabolic remodeling. Accordingly, the present invention relates to the use of O-GlcNAcase inhibitors for the treatment of acute decompensated heart failure.

IPC Classes  ?

• A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Abstract

tuberculosistuberculosis.

IPC Classes  ?

• C07D 498/04 - Ortho-condensed systems
• C07D 498/14 - Ortho-condensed systems
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• C07D 498/10 - Spiro-condensed systems
• C07D 498/20 - Spiro-condensed systems

Abstract

The invention relates to ESM-1 (Endothelial cell Specific Molecule) or a pharmaceutical composition containing it for use in a method for treating or preventing acute respiratory distress syndrome (ARDS) in a patient.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 31/12 - Antivirals
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

In the present invention, inventors demonstrate that prenatal excess of anti-Müllerian hormone triggers PCOS-like impairment in female sexual behavior in mice. Sexual dysfunction in PCOS-like mice is associated with decreased expression of neuronal nitric oxide synthase (nNOS) neurons in different hypothalamic regions known to be involved in female sexual behavior: rostral periventricular area of the third ventricle (RP3V), ventromedial nucleus of the hypothalamus (VMH), and arcuate nucleus (ARN) during estrus. Chemogenetic inhibition of nNOS neuronal activity in the ventromedial nucleus of the hypothalamus of control adult females recapitulates PCOS-like sexual dysfunction. Of clinical relevance, administration of nitric oxide (NO) donor rescues normal sexual behavior in PCOS-like mice. Accordingly, the present invention relates to invention relates to Nitric Oxyde (NO) agent for use in the prevention or the treatment of sexual dysfunction associated with Polycystic Ovary Syndrome (PCOS) or with Hypoactive Sexual Desire Disorder (HSDD) in a subject in need thereof.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives

Abstract

The invention relates to a process for producing an optical device equipped with a nano-structured or micro-structured component (21) joined to one end of an optical fibre (30), the process comprising steps of: - providing a carrier (10) based on a photosensitive material (12) that is convertible into a vitreous material, and producing on one end (10A) of said carrier, by two-photon photopolymerization, a micro-structured or nano-structured component (21) based on a photosensitive material (22) that is convertible into a vitreous material; - carrying out one or more heat treatments so as to convert the material (12) of said carrier and the material (22) of said micro- or nano-structured component into vitreous material; subsequently, - joining and securing a region of a second end (10B) of said carrier (10), which end is opposite said first end (10A), to a zone of an end of the optical fibre (30), through localized fusion of said region and of said zone, of said carrier and of said optical fibre (30), respectively.

IPC Classes  ?

• G02B 6/26 - Optical coupling means
• G02B 1/00 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements

Abstract

The invention relates to a device for trapping at least one cell pair in a solution containing at least one first cell (C1) of a first type and at least one second cell (C2) of a second type, comprising: - a microfluidic channel (3) adapted for a unidirectional flow (F) of the solution; - a first trap (1) comprising a pair of first fingers (10a, 10b) arranged in the microfluidic channel (3), at least one of said first fingers (10a, 10b) being coupled to a respective first actuator (11a, 11b), said first actuator being configured to adjust the first trap (1) along a direction transversal to the flow (F) between an open position allowing passage of the first cell between the first fingers (10a, 10b) and a closed position adapted to a size of the first cell to allow trapping the first cell between the first fingers (10a, 10b);15 - a second trap (2) comprising a pair of second fingers (20a, 20b) arranged in the microfluidic channel (3), at least one of said second fingers (20a, 20b) being coupled to a respective second actuator (21a, 21b), said second actuator being configured to adjust the second trap (2) along a direction transversal to the flow (F) between an open position allowing passage of the second cell between the second fingers (20a, 20b) and a closed position adapted to a size of the second cell to allow trapping the second cell between the second fingers (20a, 20b); wherein the first trap (1) is arranged relative to the second trap (2) so as to form, when the first and second traps are in the closed position, a cell pair comprising the trapped first and second cells such that the second cell is in physical or chemical interaction with the first cell.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

In the present invention inventors perform studies on extracellular vesicles isolated from urine samples to assess the biomarker potential of measures of the LRRK2-Rab pathway in idiopathic and LRRK2 linked PD as well as in inhibitor dosed rodents and non-human primates. Their results show modifications in the LRRK2-Rab pathway in urinary EVs, both in disease and after LRRK2 kinase inhibitor treatment. More preciasly inventors have found in a first cohort that pS1292-LRRK2 levels were elevated in individuals carrying the LRRK2 G2019S mutation, but did not differ significantly between healthy and PD groups, whether for LRRK2 G2019S carriers or not. In a second cohort, they found that PD was statistically associated to and increase in Rab8 levels and a decrease in S910-LRRK2 and S935-LRRK2 phosphorylation rates. This study assesses LRRK2 and Rabs as a disease and pharmacodynamic marker in human urine samples and this current analysis shows LRRK2 and Rab epitopes modified in patient groups.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Cisplatin is a potent chemotherapeutic drug, widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, such as neuropathy. Therefore, there is an urgent medical need to identify novel strategies limiting cisplatin-induced pain. Here, the inventors provide evidence that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW-6002) significantly protects from cisplatin-induced neuropathy in experimental models of sub-chronic cisplatin treatment. In particular, the present invention relates to a method for the treatment of neuropathy (e.g. CIPN) in a subject in need therefore comprising administering to the subject a therapeutically effective amount of a selective A2A Adenosine Receptor (A2AR) antagonist.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 33/243 - PlatinumCompounds thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 35/00 - Antineoplastic agents

Abstract

2A2A2A2AR) antagonist.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 33/243 - PlatinumCompounds thereof
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to compounds of formula (I) and the use thereof as inhibitors of P. aeruginosa virulence factor LasB. These compounds are useful in the treatment of bacterial infections, especially caused by P. aeruginosa.

IPC Classes  ?

• A61P 31/04 - Antibacterial agents
• C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
• C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention relates to methods for detecting a target in a sample using mutated nanobodies, wherein an amino acid present in the loop of the FR1 region of framework of the nanobodies is mutated to cysteine.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The present invention relates to new norbornen analogues of formula (I), wherein the norbornen moiety is in R5 and to the use of norbornen analogues as a drug, in particular for the prevention and/or treatment of a mycobacterial infection or for the prevention and/or treatment of a disease caused by infection with a mycobacterium.

IPC Classes  ?

• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61K 31/428 - Thiazoles condensed with carbocyclic rings

Abstract

The present invention relates to an adhesive composition comprising a calcium phosphate ceramic selected from tetracalcium phosphate and alpha-tricalcium phosphate, phosphorylated serine, polydopamine, and an aqueous solvent. The invention also relates to a kit, to a method for producing said adhesive composition as well as to the uses thereof.

IPC Classes  ?

• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices

Abstract

The present invention relates to antimicrobial peptides, variants and chemical analogues thereof; in particular, a peptide of 20 amino acids, named Michelicin, having the sequence RVCVRICRNGRCYRRCWNT, derived from a longer precursor with a BRICHOS domain from the marine worm Capitella. The peptide has several cysteines which form disulfide bridges and provide stability in salt conditions. Several derivatives and analogues were produced. The peptide and the derivatives show antimicrobial activity against a wide range of bacteria. The application also concerns nucleic acid sequences encoding these, pharmaceutical composition and to their use as a drug, preservative and disinfectant.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/04 - Antibacterial agents

Abstract

The invention relates to a coincidence detector for quantifying a difference in time of arrival between a first and a second signal and/or an amplitude ratio of these signals, the coincidence detector comprising: a) a first stage configured to receive the first and second signals, and to provide an output pulse having an amplitude that is proportional to the time elapsed between the instant of receipt of the first signal and the instant of receipt of the second signal, and/or proportional to the amplitude ratio of the two signals; and b) a second stage arranged to generate a number of pulses on the basis of the amplitude of the output pulse of the first stage, the number of pulses generated providing information on the difference in arrival time between the two received signals and/or on the amplitude ratio of these signals.

IPC Classes  ?

• G01S 5/22 - Position of source determined by co-ordinating a plurality of position lines defined by path-difference measurements

Abstract

The invention relates to a device (100) for loading and delivering radioactive seeds which is suitable for brachytherapy, the device comprising: - a seed reservoir (110) containing radioactive seeds which are independent of one another; - a flexible delivery wire (120), a device (130) for motorized driving and guiding of the delivery wire that is configured to move the delivery wire from a retracted position, freeing a loading area for the loading of a radioactive seed, to a deployed position for delivering the seed; and - a system for loading a seed from the reservoir to the loading area.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

A device to be implanted in a subject's body to form an implant for replacing and/or increasing a volume of soft tissue, the device being of the type including a three-dimensional frame which defines an inner space in the frame. The frame is typically bio-absorbable and includes two side apertures forming a transverse passage for inserting a vascular pedicle. The device further has at least two bio-absorbable textile sheets that can be stacked on each other in the inner space of the frame.

IPC Classes  ?

• A61F 2/12 - Mammary prostheses
• A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

Abstract

The invention relates to antibodies against extracellular epitopes of human Transient Receptor Potential Vanilloid 6 (TRPV6) channel protein, in particular antibodies which modulate TRPV6 channel activity on the plasma membrane and thereby trigger apoptosis of cancer cells expressing TRPV6. The invention relates also to the use of said antibodies for the diagnosis, prognosis and treatment of diseases involving TRPV6 channels, in particular diseases associated with TRPV6-expression such as cancers. The invention further relates to peptide antigens from human TRPV6 protein useful for the production of said antibodies.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to devices and methods for transporting and monitoring light beams, especially for so-called "lensless" endo-microscopic imaging. The present invention is for example applicable to endoscopic exploration, for example of organs of a living being whilst the latter is able to move freely during the measurement. More particularly, the present invention allows the transmission matrix of the fibre to be measured "directly", whilst the fibre potentially undergoes changes of configuration. The present invention also relates to a fibre-optic device suitable for implementing the method.

IPC Classes  ?

• G01M 11/00 - Testing of optical apparatusTesting structures by optical methods not otherwise provided for

Abstract

Investigating the impact of Tau protein expression in cancer cell lines, Inventors have demonstrated that the Tau expression is associated with an increased resistance to HDAC inhibittors. Briefly in the present invention, inventors report that Tau expression in breast cancer cell lines causes resistance to the anti-cancer effects of histone deacetylase inhibitors, by preventing histone deacetylase inhibitor-inducible gene expression and remodeling of chromatin structure. Inventors identify Tau as a protein recognizing and binding to core histone when H3 and H4 are devoid of any post-translational modifications or acetylated H4 that increases the Tau's affinity. In addition, they demonstrate that the interaction between Tau and histones prevents further histone H3 post-translational modifications induced by histone deacetylase-inhibitor treatment by maintaining a more compact chromatin structure The present invention relates to means to improve the bioavailability of histone deacetylase (HDAC) inhibitor and thereby also improve the efficacy of histone deacetylase (HDAC) inhibitor treatments.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The present disclosure relates to the field of materials capable of absorbing terahertz and millimetric waves. In particular, the present invention relates to a method for preparing a composite material consisting of a polysiloxane and graphite polymer lattice, as well as the composite material obtained by such a method and the ceramics obtainable from such a composite material.

IPC Classes  ?

• C04B 35/571 - Fine ceramics obtained from polymer precursors
• C04B 35/56 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbides

Abstract

The present invention relates to bacteria of the genus Faecalibacterium, in particular bacteria of the species F. Prausnitzii or bacteria of the species F. duncaniae, for use in the prevention or treatment of an infection in a subject with a respiratory virus, preferably a human respiratory virus.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The invention relates to a signal detector (10), in particular for radio-frequency signals, in particular a "Wake Up Radio" detector, comprising: - a first circuit (20) which receives the signal as its input and is configured to set the operation point (M) at its output at a predefined DC voltage (Vm_DC) to which a variable part (ΔVm) that is dependent on the signal of the input is added; and - a second circuit (30) which is connected at its input to the output of the first circuit (20) and is configured to amplify the variable part (ΔVm) of the signal, this second circuit comprising a chain of at least two cascading logic inverters (32) that operate below the threshold.

IPC Classes  ?

• H04B 1/24 - Circuits for receivers in which no local oscillation is generated the receiver comprising at least one semiconductor device having three or more electrodes
• H04W 52/02 - Power saving arrangements
• H04L 27/02 - Amplitude-modulated carrier systems, e.g. using on/off keyingSingle sideband or vestigial sideband modulation

Abstract

Streptococcuspneumoniaepneumoniae.

IPC Classes  ?

• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• A61P 31/04 - Antibacterial agents
• A61K 39/09 - Streptococcus

Abstract

The present invention concerns novel Gram-negative bacteria efflux pump inhibitors. It further relates to the use of Gram-negative bacteria efflux pump inhibitors to prevent and/or treat antibiotic resistance by potentiating the activity of antibiotics. Infections by multidrug resistant (MDR) Gram-negative bacteria are a major threat to global healthcare. The inventors have discovered a novel class of Resistance Nodulation cell Division-efflux pump inhibitors. The inventors tested the effects of these inhibitors on growth inhibition of different bacteria as well as their impact on the boosting of antibiotic activity in different bacteria. Particularly, the inventors tested the effects of these inhibitors on E. coli, A. baumannii, K. pneumoniae and P. aeruginosa.

IPC Classes  ?

• C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• C07D 215/38 - Nitrogen atoms
• C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
• C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
• C07D 295/073 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C07D 471/08 - Bridged systems
• C07D 487/04 - Ortho-condensed systems
• C07D 487/08 - Bridged systems
• C07D 498/04 - Ortho-condensed systems
• A61P 31/04 - Antibacterial agents
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Abstract

Disclosed are modified cytokines which, relative to wild-type forms, comprise one or more amino acid modifications. Relative to the activity of wild type cytokines, these modified cytokines exhibit enhanced activity at an acidic pH and often reduced activity at neutral pH. The disclosed modified cytokines are for use in medicine and/or for the treatment and/or prevention of an immunological condition or cancer.

IPC Classes  ?

• C07K 14/55 - IL-2

Abstract

Disclosed are modified cytokines which, relative to wild-type forms, comprise one or more amino acid modifications. Relative to the activity of wild type cytokines, these modified cytokines exhibit enhanced activity at an acidic pH and often reduced activity at neutral pH. The disclosed modified cytokines are for use in medicine and/or for the treatment and/or prevention of an immunological condition or cancer.

IPC Classes  ?

• C07K 14/55 - IL-2

Abstract

The present invention arises from a formulation study in order to define the best excipients including buffer, surfactant, sugar and amino acid to stabilize Flagellin during mesh-nebulization. One of the key factors in stabilising proteins is determining the optimal pH and buffer system to provide adequate solubility and stability and avoid aggregate formation during the aerosolization process. Different formulation have been assayed in order to obtain a stable and soluble aerosol composition comprising flagellin polypeptide in particular considering the choice of the buffering agent, the surfactant and the pH of the liquid formulation comprising the flagellin polypeptide in order to maintain the activity of the flagellin after the aerosolization process. Accordingly, the present invention relates to an aerosol composition comprising droplets comprising a liquid formulation, wherein the liquid formulation comprises a flagellin polypeptide, a buffer (acetate and/or phosphate) and a surfactant (polysorbate).The aerosol composition of the present invention is suitable for the treatment of lung bacterial infections.

IPC Classes  ?

• A61K 9/10 - DispersionsEmulsions
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The present invention relates to the use of CASD1 as a biomarker of a cancer expressing the O-acetylated-GD2 ganglioside. The present invention further concerns a method of diagnosing a cancer expressing the O-acetylated-GD2 ganglioside, a method of selecting a subject suffering from a cancer expressing the O-acetylated-GD2 ganglioside for treatment targeting said cancer, or a method of monitoring the response of a subject suffering from a cancer expressing the O-acetylated-GD2 ganglioside to a treatment targeting said cancer.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

There is a need for novel therapies for the treatment of inflammation. Now, the inventors surprisingly show that clofoctol has potent anti-inflammatory properties. In particular, the inventors demonstrate that clofoctol treatment drastically reduced pulmonary inflammation in two models that recapitulate severe inflammation, one induced by the virus SARS-CoV-2, and the other induced by LPS. Collectively, the data of the inventors justify to suggest that clofoctolwould be suitable for the treatment of inflammation in general.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/06 - Antiasthmatics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or hydrate thereof, for use in the treatment of a viral pulmonary disease or a chronic respiratory distress syndrome (CRDS) resulting from a viral pulmonary disease in a subject, said disease being different from COVID-19, wherein formula (I) is Z-R-A-R'-Y, including plerixafor.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a device for collecting a fraction of the perspiration excreted by a subject, said device being of the type comprising a multi-layer patch (1) comprising: - a first layer (61, 62, 4) comprising at least one perspiration-collecting aperture (611) and a transfer opening (41); - a hydrophilic absorbent layer (5), positioned above the first layer and communicating with the external environment, and communicating with the first layer via the transfer opening (41); - a film (7), possibly transparent, that constitutes a barrier against water and against vapour and that covers at least the upper face of the absorbent layer (5); said device notably comprising means (6) for regulating the rate at which perspiration in the liquid and/or vapour state penetrates the absorbent layer (5).

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

The present invention relates to a composition for promoting plants growth and/or for protecting plants against at least one plant pest and/or one plant disease, said composition comprising simultaneously at least one bacteria of the genus Bacillus producing antifungal lipopeptides, at least one fungi of the genus Trichoderma, and at least one nitrogen mineral source. The present invention also relates to the use of such a composition and to a method for obtaining such a composition. The present invention also relates to a co-culture medium for producing at least in part such a composition.

IPC Classes  ?

• C05C 5/02 - Fertilisers containing other nitrates containing sodium or potassium nitrate
• A01N 63/22 - Bacillus
• A01N 63/38 - Trichoderma
• C05F 11/08 - Organic fertilisers containing added bacterial cultures, mycelia or the like
• C05G 3/60 - Biocides or preservatives, e.g. disinfectants, pesticides or herbicidesPest repellants or attractants

Abstract

The invention relates to a device (5) comprising an optical surface (10) and a cleaning device (15) for cleaning the optical surface comprising: - a wave transducer (25) acoustically coupled with the optical surface and configured to synthesize an ultrasound wave (W) propagating within the optical surface, and - a spraying unit (20) for dispensing a washing liquid (L) onto the optical surface, the device being shaped so that the ultrasound wave displaces the washing liquid on the optical surface.

IPC Classes  ?

• B60S 1/02 - Cleaning windscreens, windows, or optical devices
• B08B 3/12 - Cleaning involving contact with liquid with additional treatment of the liquid or of the object being cleaned, e.g. by heat, by electricity or by vibration by sonic or ultrasonic vibrations
• B60S 1/52 - Arrangement of nozzles
• B60S 1/58 - Cleaning windscreens, windows, or optical devices specially adapted for cleaning other parts or devices than front windows or windscreens for rear windows
• G02B 27/00 - Optical systems or apparatus not provided for by any of the groups ,
• B08B 3/02 - Cleaning by the force of jets or sprays
• B08B 7/02 - Cleaning by methods not provided for in a single other subclass or a single group in this subclass by distortion, beating, or vibration of the surface to be cleaned

Abstract

The present application relates to a composition of yeast polysaccharides comprising β-(1,6)-glucans, preferably also mannans and α-glucans, characterized in that said yeast polysaccharides are extracts of yeast wall fragments. Typically, the β-glucans are β-(1,6)-glucans. It also relates to a method for obtaining such a composition comprising at least one step of fractionating a yeast wall composition and extracting an insoluble fraction, and at least one step of extracting a soluble fraction from the insoluble fraction obtained in step a). The present application lastly relates to a composition with a human or veterinary therapeutic objective, for the treatment of gastrointestinal pathologies associated with pathogenic microorganisms and also to the non-therapeutic use thereof for improving intestinal comfort.

IPC Classes  ?

• A61K 36/064 - Saccharomycetales, e.g. baker's yeast
• A61K 8/73 - Polysaccharides
• A61K 31/716 - Glucans
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to a method for rapid detection or quantification of viral particles in a sample. This method is particularly useful for rapid test of SARS-CoV-2.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses